SDSL Activators
The designation SDSL Activators encompasses a diverse array of compounds that can influence the activity of SDSL through modulation of various metabolic pathways. Compounds such as A-769662 and AICAR function as activators of AMP-activated protein kinase, a central regulator of cellular energy homeostasis, which in turn can augment the demand for SDSL function in lipid metabolism. Agonists of PPAR isoforms like GW501516, pioglitazone, fenofibrate, and OEA act on nuclear receptors that directly regulate the expression of genes involved in lipid synthesis and degradation, potentially necessitating enhanced SDSL activity to meet the altered metabolic requirements.
Other compounds, such as GW3965 and SRT1720, engage with liver X receptors and sirtuin pathways, respectively, modulating the expression of numerous genes, including those involved in lipid homeostasis, which may lead to increased SDSL activity. Pioglitazone and fenofibrate, through their actions on PPARγ and PPARα, orchestrate a wide array of lipid metabolic processes that can indirectly necessitate the activation of SDSL. Furthermore, molecules like 4-Phenylbutyrate and nicotinamide riboside can induce changes in gene expression and NAD+ metabolism, respectively, thereby influencing the activity of SDSL. Choline, an essential nutrient, plays a pivotal role in lipid metabolism, and its availability can impact the function of lipid-metabolizing enzymes, including SDSL.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
Activates AMPK which in turn can enhance fatty acid oxidation and indirectly stimulate SDSL activity due to shifts in lipid metabolism. | ||||||
GW501516 | 317318-70-0 | sc-202642 sc-202642A | 1 mg 5 mg | $82.00 $179.00 | 28 | |
Activates PPARδ influencing genes involved in lipid catabolism and biosynthesis, potentially increasing demand for SDSL activity. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
Activates AMPK leading to altered lipid metabolism which may enhance SDSL activity. | ||||||
GW 3965 hydrochloride | 405911-17-3 | sc-224011 sc-224011A sc-224011B | 5 mg 25 mg 1 g | $140.00 $483.00 $3121.00 | ||
Activates liver X receptors (LXRs) which regulate lipid metabolism genes, potentially upregulating SDSL. | ||||||
SRT1720 | 1001645-58-4 | sc-364624 sc-364624A | 5 mg 10 mg | $197.00 $364.00 | 13 | |
SIRT1 activator that can modulate lipid homeostasis, possibly leading to increased SDSL activity. | ||||||
Palmitoleic acid | 373-49-9 | sc-205424 sc-205424A sc-205424B sc-205424C sc-205424D | 100 mg 500 mg 1 g 5 g 10 g | $33.00 $135.00 $238.00 $1039.00 $1907.00 | 4 | |
Monounsaturated fatty acid that may serve as a substrate or regulator for SDSL function. | ||||||
4-Phenylbutyric acid | 1821-12-1 | sc-232961 sc-232961A sc-232961B | 25 g 100 g 500 g | $53.00 $136.00 $418.00 | 10 | |
Histone deacetylase inhibitor, modifies chromatin and gene expression, potentially increasing SDSL gene transcription. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
PPARγ agonist that can modulate lipid metabolism, potentially influencing SDSL activity. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
PPARα agonist that influences lipid catabolism and may affect SDSL activity. | ||||||
Oleylethanolamide | 111-58-0 | sc-201400 sc-201400A | 10 mg 50 mg | $90.00 $194.00 | 1 | |
PPARα agonist, modulates lipid signaling, could enhance SDSL activity. | ||||||